Drug Trial Radar · NCT04590599
A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
Last checked: Nov 19, 2026Latest source record: Dec 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
205
Actual
Start
Dec 8, 2020
Primary completion
Nov 20, 2023
Study completion Nov 20, 2023
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, controlled, parallel-cohort Phase II clinical study, which is planned to enroll 220 subjects with advanced cervical cancer who have failed or cannot tolerate first-line or above platinum-based chemotherapy
Conditions
- Advanced Cervical Cancer
Interventions
IBI310Drug
IBI310 3 mg/kg,Q3W, for a total of 4 cycles
PlaceboDrug
Placebo Q3W, for a total of 4 cycles
SintilimabDrug
Sintilimab 200mg,Q3W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Assessed week 6,week 12,week 18 ,and every 9 weeks (or every 12 weeks after 54 weeks of treatment) for duration of study participation which is estimated to be 24 months.
- Objective response rate (ORR)Time frame: Assessed week 6,week 12,week 18 ,and every 9 weeks (or every 12 weeks after 54 weeks of treatment) for duration of study participation which is estimated to be 24 months.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Zhenjiang, China
Innovent Biologics, Inc.
Suzhou, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.